June 5, 2017

Cutting Edge Science Meeting Series to End the Opioid Crisis

Participant List — Medications Development for Opioid Use Disorders and Overdose Prevention and Reversal

Participant List

Katherine L. Beebe, Ph.D.
Executive Vice President, Chief Development Officer Titan Pharmaceuticals, Inc.

Andrew Bellinger, M.D., Ph.D.
Chief Scientific Officer, Lyndra

Anton Bespalov, M.D.
Co-Founder and Managing Partner Partnership for Assessment and Accreditation of Scientific Practice

Robert Brooner, Ph.D.
Director
Addiction Treatment Services Professor of Psychiatry and Behavioral Sciences Johns Hopkins Medicine

Francis S. Collins, M.D., Ph.D.
Director
National Institutes of Health

Roger Crystal, M.D.
Chief Executive Officer
Opiant Pharmaceuticals, Inc.

Kathryn Cunningham, Ph.D.
Chauncey Leake Distinguished Professor of Pharmacology Vice Chairman
Department of Pharmacology and Toxicology Director
Center for Addiction Research

Gail D’Onofrio, M.D.
Professor of Emergency Medicine
Chair, Department of Emergency Medicine
Yale School of Medicine

Carlos Del Rio, M.D.
Professor of Medicine
Emory School of Medicine

Stephen Doberstein, Ph.D.
Senior Vice President and Chief Scientific Officer
Nektar Therapeutics

Elliot Ehrich, M.D.
Executive Vice President
Research and Development
Alkermes

Sergi Ferré, M.D., Ph.D.
Senior Investigator, Chief
Integrative Neurobiology Section
Intramural Research Program, National Institute on Drug Abuse

Gary Fujii, Ph.D.
President & Chief Executive Officer
Molecular Express

Jeet Guram, M.D.
Chief Medical Officer
Centers for Medicare & Medicaid Services

Christian Heidbreder, Ph.D.
Chief Scientific Officer
Indivior

Sharon Hertz, M.D.
Division Director
Division of Anesthesia, Analgesia, and Addiction Products
Food and Drug Administration

Thomas J. Hudzik, Ph.D.
Senior Consultant
ALA BioPharma Consulting

Pedro Irazoqui, Ph.D.
Associate Head of Biomedical Engineering Professor of Biomedical Engineering
Showalter Faculty Scholar
Professor of Electrical and Computer Engineering
Director, Center for Implantable Devices Weldon School of Biomedical Engineering Purdue University

Kim Janda, Ph.D.
Ely R. Callaway, Jr. Professor of Chemistry Professor, 
Director, Worm Institute for Research & Medicine
Skaggs Scholar, The Skaggs Institute for Chemical Biology
Department of Chemistry Chemistry, Scripps Research Institute

Howard Levin, M.D.
President and Chief Scientific Officer
Coridea, LLC

Donald Mackenzie, Ph.D.
Vice President Head Global Formulation Development
GSK

Gary Matyas, Ph.D.
Chief, Adjuvants and Formulations
US Military HIV Research Program
Walter Reed Army Institute of Research

Joe Menetski, Ph.D.
Deputy Director
Research Partnerships
NIH Foundation

Seamus Mulligan
Chairman & Chief Executive Officer
Adapt Pharma

Amy Newman, Ph.D.
Deputy Scientific Director
Intramural Research Program
National Institute on Drug Abuse

Jessica Hulsey Nickel
President & Chief Executive Officer, Addiction Policy Forum

Edward Nunes, M.D.
Professor of Psychiatry
Columbia University

S. Michael Owens, Ph.D.
Chief Scientific Officer, Professor and Director,
Center for Alcohol and Drug Abuse
Wilbur Mills Endowed Chair in Alcohol and Drug Abuse Prevention
University of Arkansas for Medical Sciences

Kinam Park, Ph.D.
Showalter Distinguished Professor of Biomedical Engineering
Professor of Pharmaceutics
Purdue University

Gavril Pasternak, M.D., Ph.D.
Anne Burnett Tandy Chair of Neurology
Memorial Sloan-Kettering Cancer Center

Paul Pentel, M.D.
Professor of Medicinen
University of Minnesota Department of Medicine

Daniele Piomelli, Ph.D., Pharm.D.
Professor
Anatomy & Neurobiology, Department of Anatomy & Neurobiology
Louise Turner Arnold Chair in Neurosciences School of Medicine
University of California, Irvine

Colleen Ruegger, Ph.D.
Global Head of Oral Pharmaceutical Development
Novartis Pharmaceutical Corporation

Seddon Savage, M.D.
Adjunct Associate Professor of Anesthesiology Geisel School of Medicine
Dartmouth College

Behshad Sheldon
President & Chief Executive Officer,
The University of Texas Medical Branch
Braeburn Pharmaceuticals

Lawrence A. Tabak, D.D.S., Ph.D.
Principle Deputy Director
National Institutes of Health

Douglas Throckmorton, M.D.
Deputy Center Director for Regulatory Programs
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Food and Drug Administration

Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

Sharon Walsh, Ph.D.
Professor, Behavioral Science
University of Kentucky College of Medicine

Janet Woodcock, M.D.
Director, Center for Drug Evaluation and Research
Food and Drug Administration

This page last reviewed on November 21, 2017